#1 Clinical Trials Search in Europe

Omo-103

OMO-103 is an innovative drug currently being studied in clinical trials for its potential in treating advanced high-grade osteosarcoma and metastatic pancreatic cancer. This article delves into the ongoing research, exploring how this Myc inhibitor is being evaluated for safety, efficacy, and its impact on patients’ quality of life in these challenging cancer types.

Table of Contents

What is OMO-103?

OMO-103 is a new experimental drug that is currently being studied for its potential to treat various types of advanced cancers[1][2]. It belongs to a class of medications known as Myc inhibitors. Myc is a protein that plays a crucial role in cell growth and division. In many types of cancer, Myc is overactive, leading to uncontrolled cell growth. By inhibiting or blocking Myc, OMO-103 aims to slow down or stop the growth of cancer cells.

How does OMO-103 work?

OMO-103 works by targeting and inhibiting the Myc protein[1][2]. In normal cells, Myc helps regulate cell growth and division. However, in many cancers, Myc becomes overactive, causing cells to grow and divide too quickly. By blocking Myc, OMO-103 aims to:

  • Slow down or stop the growth of cancer cells
  • Potentially cause cancer cells to die
  • Prevent cancer from spreading to other parts of the body
This approach is particularly promising because Myc is involved in many different types of cancer, making OMO-103 a potential treatment for various cancer types.

Which cancers does OMO-103 target?

Based on the current clinical trials, OMO-103 is being studied for the treatment of two specific types of cancer:

  1. Advanced High-Grade Osteosarcoma: This is a type of bone cancer that typically affects children and young adults. It’s considered “high-grade” because the cancer cells look very abnormal under a microscope and tend to grow and spread quickly[1].
  2. Metastatic Pancreatic Cancer: This is pancreatic cancer that has spread to other parts of the body. Pancreatic cancer is known to be particularly aggressive and difficult to treat[2].
It’s important to note that as research continues, OMO-103 may be found to be effective against other types of cancers as well.

How is OMO-103 administered?

OMO-103 is administered through intravenous (IV) infusion. This means the drug is given directly into a vein through a needle or catheter. Based on the clinical trial information:

  • For osteosarcoma patients, OMO-103 is given at a dose of 6.5 mg/kg as a weekly IV infusion[1].
  • For pancreatic cancer patients, OMO-103 is given in combination with standard chemotherapy drugs (gemcitabine and nab-paclitaxel)[2].
The exact dosing and schedule may vary depending on the specific trial and the patient’s individual needs.

Current Clinical Trials

OMO-103 is currently being studied in two main clinical trials:

  1. Phase 2 Pilot Study for Osteosarcoma: This trial is testing OMO-103 in patients with advanced high-grade osteosarcoma. It aims to enroll 10 evaluable patients, with at least 30% of patients being under 18 years old[1].
  2. Phase 1b Study for Pancreatic Cancer: This trial is evaluating OMO-103 in combination with standard chemotherapy (gemcitabine and nab-paclitaxel) in patients with metastatic pancreatic cancer who haven’t received previous treatment for advanced disease[2].
These trials are designed to assess the safety, effectiveness, and proper dosing of OMO-103.

Potential Benefits and Side Effects

The potential benefits of OMO-103 include:

  • Slowing down or stopping cancer growth
  • Shrinking tumors
  • Improving survival rates
  • Providing a new treatment option for cancers that are difficult to treat
However, as with all medications, OMO-103 may cause side effects. The clinical trials are carefully monitoring for any adverse events (side effects). Common side effects of cancer treatments can include fatigue, nausea, and changes in blood cell counts. The specific side effects of OMO-103 will become clearer as the clinical trials progress[1][2].

Quality of Life Considerations

An important aspect of cancer treatment is how it affects a patient’s quality of life. Both clinical trials for OMO-103 are including quality of life assessments:

  • For adult patients, the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-C30) is being used[1][2].
  • For patients between 12 and 17 years old in the osteosarcoma trial, the Pediatric Quality of Life Inventory (PedsQL) is being used[1].
  • For pancreatic cancer patients, an additional questionnaire specific to pancreatic cancer (QLQ-PAN26) is being used[2].
These assessments help researchers understand how the treatment affects patients’ daily lives, including physical, emotional, and social functioning.

Aspect Osteosarcoma Trial Pancreatic Cancer Trial
Study Phase Phase 2 Phase 1b
Patient Population Advanced high-grade osteosarcoma, including children Metastatic pancreatic cancer, treatment-naïve
Treatment OMO-103 monotherapy OMO-103 + gemcitabine/nab-paclitaxel
Dosing 6.5 mg/kg weekly IV infusion To be determined in study
Primary Outcomes 16-week progression-free survival rate Safety and tolerability
Key Secondary Outcomes Objective response rate, disease control rate, overall survival Objective response rate, pharmacokinetics, quality of life
Quality of Life Assessment EORTC-C30 for adults, PedsQL for 12-17 years old EORTC QLQ-C30 and QLQ-PAN26

FAQ

  • What is OMO-103 and how does it work? OMO-103 is a Myc inhibitor, which means it targets a specific protein involved in cancer growth. It's being studied as a potential treatment for advanced high-grade osteosarcoma and metastatic pancreatic cancer. The drug is administered intravenously on a weekly basis.
  • What types of cancer are being studied with OMO-103? Currently, OMO-103 is being investigated in clinical trials for advanced high-grade osteosarcoma, including in children, and metastatic pancreatic cancer. These are both challenging cancer types that often have limited treatment options.
  • How is OMO-103 being administered in the trials? In the osteosarcoma trial, OMO-103 is being administered at a dose of 6.5 mg/kg as a weekly intravenous infusion in 28-day cycles. For the pancreatic cancer trial, it's being studied in combination with standard chemotherapy drugs gemcitabine and nab-paclitaxel.
  • What are the main goals of these clinical trials? The main goals of these trials are to evaluate the safety and effectiveness of OMO-103. Researchers are looking at how well it controls tumor growth, how long patients survive without their disease getting worse, and if there are any side effects. They're also studying how the drug moves through the body and its impact on patients' quality of life.
  • How is the effectiveness of OMO-103 being measured? The effectiveness of OMO-103 is being measured in several ways. These include looking at how many patients' tumors shrink or stop growing, how long it takes for the cancer to start growing again, and how long patients survive overall. Researchers are also using special scans to measure changes in tumor size and volume.

Ongoing Clinical Trials on Omo-103

  • Study on the Safety and Tumor-Fighting Effects of OMO-103 for Patients with Advanced Osteosarcoma

    Not yet recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Osteosarcoma: A type of bone cancer that begins in the cells that form bones. It occurs most often in the long bones of the arms and legs.
  • Metastatic Pancreatic Cancer: A cancer that started in the pancreas but has spread to other parts of the body.
  • Myc Inhibitor: A type of drug that blocks the action of Myc, a protein involved in cell growth and division that is often overactive in cancer cells.
  • Intravenous (IV) Infusion: A method of delivering medications directly into the bloodstream through a vein.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Objective Response Rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • Disease Control Rate (DCR): The percentage of patients whose cancer shrinks or remains stable in response to treatment.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Adverse Events (AEs): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Quality of Life (QoL): A measure of an individual's well-being and ability to carry out daily activities while dealing with illness and treatment.

References

  1. https://clinicaltrials.gov/study/NCT06650514
  2. https://clinicaltrials.gov/study/NCT06059001